Skip to main content
. Author manuscript; available in PMC: 2012 Jan 30.
Published in final edited form as: Clin Cancer Res. 2008 Oct 1;14(19):6005–6013. doi: 10.1158/1078-0432.CCR-08-0216

Figure 2.

Figure 2

A dichotomous heat map of tumor methylation, mutation status, and selected clinicopathologic features. The DNA methylation status of 161 primary colorectal tumors were determined using the five CIMP markers p16INK4a, p14ARF, MGMT, RARβ and TIMP3. For each gene, instead of displaying the methylation levels of individual CpG sites, only the final methylation status of each promoter, either methylated or unmethylated, is indicated. A tumor was considered CIMP-positive if at least four of the five markers were methylated. The MSI, BRAF and KRAS mutation statuses were determined for each tumor sample. The alignment of each tumor is maintained across. The presence of hypermethylation, CIMP-positive, MSI, proximal side of colon, male gender, BRAF and KRAS mutations are indicated in red. The presence of unmethylated genes, CIMP-negative, non-MSI, distal side of colon, female gender, BRAF and KRAS wild-type alleles are indicated in green. The pink color in the CIMP column represents tumor samples with hypermethylation in three of the five markers. Few samples with no informative MSI, BRAF and KRAS mutation data are indicated in white.